de Souza Daniel Vitor, Dos Anjos Rosario Barbara, Takeshita Wilton Mitsunari, de Barros Viana Milena, Nagaoka Marcia Regina, Dos Santos Jean Nunes, Ribeiro Daniel Araki
Department of Biosciences, Institute of Health and Society, Federal University of São Paulo, UNIFESP, Santos, SP, Brazil.
Department of Dentistry, Federal University of Sergipe, UFS, Aracaju, SE, Brazil.
Pathol Res Pract. 2022 Apr;232:153828. doi: 10.1016/j.prp.2022.153828. Epub 2022 Feb 25.
This systematic review (SR) with meta-analysis aimed to evaluate the scientific data related to cytogenetic damage in oral exfoliated cells of patients diagnosed with oral potentially malignant disorders (OPMDs). The SR was conducted according to the PRISMA-P guidelines. The PICOS (Participants, Intervention, Comparison, Outcome, and Study Design) strategy was used to answer the question: "Is micronucleus assay in oral exfoliated cells a suitable biomarker for predicting cancer risk in individuals with OPMDs?" The search strategy was performed in the following electronic databases: PubMed, Medline, Scopus and Web of Science. The comparisons were defined as standardized mean difference (SMD), and 95% confidence intervals (CI). The quality of included studies was assessed using the EPHPP (Effective Public Health Practice Project). The GRADE tool was also utilized to assess the quality of evidence of the SR. A total of 110 potentially relevant studies were selected through the search strategy. After screening titles and abstracts, 20 full-text manuscripts were assessed for eligibility and three observational studies were included in the meta-analysis. After reviewing the 20 studies, 13 were considered weak. The meta-analysis data revealed a statistically significant difference in oral micronucleated cells by patients with OPMDs when compared to control (SMD=1.77, 95% CI, 0.36-3.18, p = 0.01), with a Tau = 1.97; Chi = 66.64, and p < 0.001. Patients with OPMDs had a positive response related to mutagenicity in oral cells compared to control patients. However, SR was not able to validate the micronucleus assay as a putative biomarker in individuals with oral potentially malignant disorders since the majority of studies were considered weak based on high risk of bias.
这项带有荟萃分析的系统评价（SR）旨在评估与被诊断为口腔潜在恶性疾病（OPMDs）患者的口腔脱落细胞中细胞遗传学损伤相关的科学数据。该系统评价是根据PRISMA-P指南进行的。采用PICOS（参与者、干预措施、对照、结局和研究设计）策略来回答问题：“口腔脱落细胞中的微核试验是否是预测OPMDs个体癌症风险的合适生物标志物？”检索策略在以下电子数据库中进行：PubMed、Medline、Scopus和科学网。比较指标定义为标准化均数差（SMD）和95%置信区间（CI）。采用有效公共卫生实践项目（EPHPP）评估纳入研究的质量。还使用GRADE工具评估系统评价的证据质量。通过检索策略共筛选出110项潜在相关研究。在筛选标题和摘要后，对20篇全文手稿进行了资格评估，3项观察性研究被纳入荟萃分析。在审查这20项研究后，13项被认为质量较差。荟萃分析数据显示，与对照组相比，OPMDs患者的口腔微核细胞存在统计学显著差异（SMD=1.77，95%CI，0.36 - 3.18，p = 0.01），Tau = 1.97；Chi = 66.64，p < 0.001。与对照患者相比，OPMDs患者口腔细胞中的致突变性呈阳性反应。然而，由于大多数研究基于高偏倚风险被认为质量较差，系统评价无法验证微核试验作为口腔潜在恶性疾病个体的假定生物标志物。
